Wednesday, 01 April 2020

Project List

Cohort Event Monitoring of Artemisinin combination therapies (ACTs)

Malaria is a leading cause of mortality and morbidity in Zimbabwe. Due to the increase in cases of resistance to anti-malarials such as chloroquine, the World Health Organisation (WHO) and the Ministry of Health and Child Welfare (of Zimbabwe) is now promoting the use of artemisinin combination therapies (ACTs) for the treatment of uncomplicated acute falciparum malaria. Although ACTs are known to be safe and effective, their safety under large-scale operational use has not been fully assessed particularly among children and pregnant women. This project aims to assess the safety of ACTs among the Zimbabwean population.

Cohort Event Monitoring is a method where information is collected, with focus on events, an all patients in a group being treated with a medicine or group of medicines. The cohort is selected without bias from all patients being treated with the monitored medicine, and the events include also incidents, not only adverse drug reactions (ADRs)

The specific objectives of this project are to:

  •  Detect signals of unrecognised reactions.
  • Identify interactions with other medicines, complementary and alternative medicines and foods
  • Identify risk factors so that they can be avoided.
  • Assess the safety of ACTs in pregnancy and lactation
  • Provide evidence for effective risk management i.e benefit/harm assessment.

Future projects:

  • Cohort Event Monitoring of Anti-tubercle and antiretroviral medicines in the public sector in Zimbabwe.
  • Post-market surveillance of antiretroviral and anti-tubercle medicines in Zimbabwe.


Latest News

Draft SADC Variations Guidelines

20 March 2020

Draft SADC Variations Guidelines are now available  Click the following links to download the guidelines and the comments sheet Draft SADC Variations Guidelines Draft SADC Variations Guidelines Comments Sheet

Medicines Information Bulletin - 2019

20 December 2019
Medicines Information Bulletin - 2019

Inside this issue: E-Reporting Tools Safety Notifications for Fluoroquinolones and Quinolones Antibiotics Notification of a potential risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) in patients treated...

Code of Ethics

22 August 2019
Code of Ethics

  In pursuit of promoting high ethical standards, the Authority has formulated a Code of Ethics for its employees and members of the Authority .The Authority believes that high ethical...

SADC Guideline on Product Information and Labeling

10 July 2019
SADC Guideline on Product Information and Labeling

  Southern African Development Community (SADC), as a region has harmonized medicines registration guidelines in the common technical document (CTD) format that were approved in January 2015. Nevertheless, the harmonization...

Draft Guidelines For Comments Only: Guideline for Submitting Application for Variations to Registered Medicines

17 May 2019
Draft Guidelines For Comments Only: Guideline for Submitting Application for Variations to Registered Medicines

In line with the WHO guidelines on variations and other SRA guidelines, the EVR Division is updating the MCAZ Guidelines for submitting applications for Variations to Registered Medicines. The update...

Careers @ MCAZ

30 October 2018

The Medicines Control Authority of Zimbabwe (MCAZ) is inviting suitably qualified, honest, self-motivated applicants for the following post: REGULATORY OFFICER x1 POST - LICENSING AND ENFORCEMENT DIVISION Reporting to the...

Fellowship in regulatory science for African Medicine Reviewers/Assessors

26 October 2018
Fellowship in regulatory science for African Medicine Reviewers/Assessors

  Background   The Medicines Control Authority of Zimbabwe (MCAZ) Regional Centre of Regulatory Excellence (ReCORE) in partnership with the European and Developing Countries Clinical Trials Partnership (EDCTP) is offering...

Quality Policy Statement

06 July 2018
Quality Policy Statement

The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient...

MCAZ Newsletter

10 May 2018
MCAZ Newsletter

In this issue: MCAZ turns 20 years Basics of reporting Side Effects of medicines Electronic Adverse Drug Reaction Reporting   For more information Please click here to download the Newsletter...

Medicines Information Bulletin - 2018

02 February 2018
Medicines Information Bulletin - 2018

Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme Click here to download the 2018 Drug Information Bulletin